GHK-Cu vs. Matrixyl: Comparing Two Skincare Peptides

The 2005 study evaluated a palmitoyl pentapeptide preparation in a 12-week, double-blind, placebo-controlled, split-face trial of 93 women with photoaged facial skin. The investigators reported improvement in wrinkle measures relative to the comparison preparation. This is human facial evidence for the formulation tested, not for every peptide product. [1]

The authors were affiliated with Procter & Gamble. That cosmetics-industry involvement is relevant to interpretation; the study should not be described as independent of the manufacturer. [1]

GHK-Cu has collagen-synthesis findings in cultured fibroblasts and connective-tissue accumulation findings in rat wounds. These experiments measured biological endpoints in different models, not a head-to-head facial test of the two peptide preparations. [2,3]

Badenhorst and colleagues published a 2016 paper combining cellular research with facial wrinkle assessment. Its human study involved 39 volunteers and tested a specific GHK-Cu nano-lipid formulation against particular comparison preparations: a carrier control and a Matrixyl 3000 product. The 2018 GHK review describes this as a randomized, double-blind comparison and reports a wrinkle-volume result favoring the tested GHK-Cu formulation. This named report should be acknowledged rather than claiming no comparison exists; its findings concern those preparations, not all GHK-Cu or Matrixyl products. [4,5]

A result for a particular delivery system and particular comparator cannot establish that GHK-Cu is universally better than palmitoyl pentapeptide or other products carrying the Matrixyl name. The review’s summary also should not be presented as an independently reproduced result. [1,4,5]

The 2016 investigators include University of Auckland researchers and a Dermatest GmbH-affiliated coauthor; the human trial was conducted at Dermatest. The paper discloses funding by Snowberry New Zealand Ltd in collaboration with Callaghan Innovation, and states that Snowberry had no involvement in data collection, analysis, interpretation, the decision to submit, or writing the manuscript. These commercial connections should remain visible. The 2018 review authors list R&D Skin Biology as their affiliation; that separate review reports no external funding and declares no conflict of interest. [4,5]